Kura Oncology, Inc. (KURA)
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid…
Descriptive
Exchange
Industry
Country
Active:none
| Company | Rating | |||||
|---|---|---|---|---|---|---|
| Loading data… | ||||||
Saved screens and full data - with a subscription
Subscribe to save filters and unlock all columns and ratings.
Subscribe - €24.90/mo